pharma news

Sep 21, 2021

Win-win for Biogen as its Biosimilar Gets Approval for AMD  Samsung Bioepis and Biogen's biosimilar drug, Byooviz, received USFDA approval for the treatment of vision loss, Age-related macular degeneration and has become the first biosimilar to Lucentis in the AMD market. The Lucentis copycat had also manag...

Sep 16, 2021

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Sep 14, 2021

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series ...

Sep 09, 2021

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indic...

Sep 07, 2021

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia ...

Aug 31, 2021

FDA's Green Flag to Ascendis's Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency For the treatment of growth failure due to deficiency of growth hormones, the USFDA approved Ascendis Pharma's Skytrofa (lonapegsomatropin-tcgd) for children of one year and older suffering from an improper s...

Aug 26, 2021

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technol...

Aug 24, 2021

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Aug 17, 2021

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC) The FDA approved the combination of Keytruda and Lenvima produced by Merck and Eisai, as a first-line treatment of adult patients with advanced renal cell carcinoma (RCC). The efficacy and safety resul...

Aug 12, 2021

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech's heart with USD 19 million.  The two-year-old Canadian biotech will utiliz...